Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...

The CDC now recommends 11 vaccines for routine administration in childhood, which it says better allows for “flexibility and ...

Arrowhead Pharmaceuticals has received authorisation from Health Canada for its siRNA medicine, Redemplo, for adults with FCS ...

Reporter Ross Law and editors Abigail Beaney and Robert Barrie reflect on a busy 2025, along with discusing forecasts for ...

According to the registration form, Aktis intends to use a large portion of the IPO proceeds on the two programmes. Around ...

Sanofi's $2.56bn bispecific autoimmune deal with Earendil Labs is the second in recent history, and will bolster the French ...

Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in ...

Insilico Medicine has entered a multi-year R&D collaboration with Servier, worth up to $888m, to develop and discover new ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

The approval marks the first new pharmacologic treatment in motion sickness in over four decades. The US Food and Drug ...

Outlook Therapeutics has received the US FDA's CRL regarding the BLA resubmission for ONS-5010/LYTENAVA to treat wet AMD.

Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for ...